Sims Michael W, Margolis David J, Localio A Russell, Panettieri Reynold A, Kawut Steven M, Christie Jason D
Pulmonary, Allergy, and Critical Care Division, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA; Airways Biology Initiative, Department of Medicine, and the Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Airways Biology Initiative, Department of Medicine, and the Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Chest. 2009 Aug;136(2):412-419. doi: 10.1378/chest.08-2739. Epub 2009 Mar 24.
Although pulmonary hypertension commonly complicates COPD, the functional consequences of increased pulmonary artery pressures in patients with this condition remain poorly defined.
We conducted a cross-sectional analysis of a cohort of 362 patients with severe COPD who were evaluated for lung transplantation. Patients with pulmonary hemodynamics measured by cardiac catheterization and available 6-min walk test results were included. The association of mean pulmonary artery pressure (mPAP) with pulmonary function, echocardiographic variables, and 6-min walk distance was assessed.
The prevalence of pulmonary hypertension (mPAP, > 25 mm Hg; pulmonary artery occlusion pressure [PAOP], < 16 mm Hg) was 23% (95% confidence interval, 19 to 27%). In bivariate analysis, higher mPAP was associated with lower FVC and FEV(1), higher Pco(2) and lower Po(2) in arterial blood, and more right heart dysfunction. Multivariate analysis demonstrated that higher mPAP was associated with shorter distance walked in 6 min, even after adjustment for age, gender, race, height, weight, FEV(1), and PAOP (-11 m for every 5 mm Hg rise in mPAP; 95% confidence interval, -21 to -0.7; p = 0.04).
Higher pulmonary artery pressures are associated with reduced exercise function in patients with severe COPD, even after controlling for demographics, anthropomorphics, severity of airflow obstruction, and PAOP. Whether treatments aimed at lowering pulmonary artery pressures may improve clinical outcomes in COPD, however, remains unknown.
虽然肺动脉高压常使慢性阻塞性肺疾病(COPD)病情复杂化,但这种情况下肺动脉压力升高的功能后果仍未明确界定。
我们对362例接受肺移植评估的重度COPD患者队列进行了横断面分析。纳入通过心导管检查测量肺血流动力学且有可用6分钟步行试验结果的患者。评估平均肺动脉压(mPAP)与肺功能、超声心动图变量及6分钟步行距离之间的关联。
肺动脉高压(mPAP>25mmHg;肺动脉闭塞压[PAOP]<16mmHg)的患病率为23%(95%置信区间为19%至27%)。在双变量分析中,较高的mPAP与较低的用力肺活量(FVC)和第1秒用力呼气容积(FEV₁)、动脉血中较高的二氧化碳分压(Pco₂)和较低的氧分压(Po₂)以及更严重的右心功能不全相关。多变量分析表明,即使在调整年龄、性别、种族、身高、体重、FEV₁和PAOP后,较高的mPAP仍与6分钟内步行距离较短相关(mPAP每升高5mmHg,步行距离缩短11m;95%置信区间为-21至-0.7;p = 0.04)。
即使在控制了人口统计学、人体测量学、气流阻塞严重程度和PAOP之后,重度COPD患者中较高的肺动脉压力仍与运动功能降低相关。然而,旨在降低肺动脉压力的治疗是否能改善COPD的临床结局仍不清楚。